Rehaler A/S announces appointment of Henrik Olsen as new CEO
Rehaler A/S today announces the appointment of Henrik Olsen as its new CEO. He will replace co-founder Troels Johansen, who will continue in the company as CTO and a vital member of the management team, focusing on bringing our Rehaler product through clinical trials as well as ensuring progress of our R&D portfolio and manufacturing.
Aarhus, Denmark – June 29, 2023
Henrik Olsen brings 27+ years of experience within Medtech to the position, having worked previously as CEO in Vigmed AB (publ) and earlier held VP positions within Business Development, Marketing and Sales in Coloplast A/S.
“We’re confident that Henrik Olsen can guide this company into the future. With Henrik’s vast international experience within medtech and particular his commercial experience from both large cap and small cap, Henrik has a strong mix of competencies needed to take Rehaler into the commercial phase” said Thomas Feldthus, Chairman of the Board.
Henrik Olsen initiated the transition into the CEO role on June 15th, and will assume full responsibility before the end of June.
Kontakter
Henrik OlsenCEO
Tlf:+45 5367 5377ho@rehaler.comTroels JohansenCTO
Tlf:+45 4097 7313tj@rehaler.comBilleder
Links
About Rehaler A/S
Rehaler is a private medical technology company developing and commercializing novel treatments based on modulation of CO2 and oxygen in the central nervous system. Rehaler has obtained proof-of-concept for its first product, a pocket sized device for treatment of migraine with aura. Rehaler recently initiated its pivotal clinical registration study which will pave the way for FDA approval, commercial launch and market adoption. The company’s technology platform has applications in several other neurological disorders which will be investigated alongside the registration study.
Følg pressemeddelelser fra Rehaler A/S
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Rehaler A/S
Rehaler modtager bevilling på 2.18 mio. kr. fra Innovationsfonden til ny migræne-behandling6.4.2022 10:50:00 CEST | Pressemeddelelse
Innovationsfonden har tildelt Rehaler en Innobooster- bevilling på 2.18 mio. kr. til det kliniske forsøg som skal dokumentere effekten af den danske medtech-virksomheds device til behandling af migræne. Forsøget gennemføres i samarbejde med hovedpinecentre i USA, Tyskland, Italien og Storbritannien. Et positivt resultat vil åbne for FDA-godkendelse og global kommercialisering af Rehaler-produktet
Rehaler closes financing round and strengthens Board of Directors1.12.2021 11:30:00 CET | Press release
Financing round of 6.1 MDKK Proceeds will be used to prepare for a clinical registration study in patients with migraine with aura Four new members with significant experience from the medical technology industry elected to the Board of Directors Rehaler, a private medical technology company focusing on an innovative treatment solution for migraine with aura, today announced the successful closing of a finance round totaling 6.1 MDKK and the appointment of Mette Gross, Martin Møller, Helene Quie and Martin Waleij to its Board of Directors. “We are very pleased with having received the confidence of several knowledgeable and experienced Scandinavian private investors. This financing will be used to mature the company and prepare for a pivotal clinical registration study for our novel device which represents a new treatment option for patients with migraine with aura. The objective is to obtain registration in the U.S. and create data supporting the commercialization of the device in bot